Genzyme is a pioneer in the development of therapies for patients affected by rare and debilitating diseases. Founded in Boston, Massachusetts in 1981, Genzyme evolved from a start-up with just a few employees to one of the world's leading biotech companies. They have been carrying out world-class research with a focus on rare diseases, particularly multiple sclerosis for over 30 years. In 2011 Genzyme was acquired by Sanofi, and as such now benefits from the reach and resources of one of the world’s largest pharmaceutical companies. Genzyme’s transformative therapies are marketed in countries around the world.